The vaccine FluMist, manufactured by MedImmune, which was acquired by AstraZeneca in 2007, was first approved by the FDA in 2003 for individuals between five and 49 years of age. Its approval has ...
PLDT Inc. shares fell last week following a United States court’s approval of its $3-million lawsuit settlement. The telecommunications company ranked 12th in value turnover, with P1.02 billion worth ...
The Central Electricity Authority (CEA) has approved two additional hydro-pumped storage projects (PSPs) in Maharashtra to ensure India’s renewable energy goals, the Ministry of Power said on Sunday.
The biotech stock's price-to-earnings-to-growth (PEG) ratio is a super-low 0.58, according to the London Stock Exchange Group (LSEG). Any PEG ratio below 1.0 is viewed as an attractive valuation.